{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens the repertoire of tumor antigens presented to T cells.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
          "line_ref": "L28"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "The tumor sensitization effect by mRNA vaccination is dependent on the downstream signaling of Type I interferon.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
          "line_ref": "L31"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "The combination of intratumoral mRNA vaccine and ICI therapy significantly increases immune cell infiltration into the tumor microenvironment.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
          "line_ref": "L33"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination correlates with improved survival outcomes for metastatic patients treated with immune checkpoint blockade.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A",
          "line_ref": "L30"
        },
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation."
    }
  ]
}